What is MediWound?
Founded in 2001 and headquartered in Israel, MediWound operates as a fully integrated biopharmaceutical entity. The company is primarily recognized for its patented proteolytic enzyme technology, which provides a unique mechanism for addressing severe burns, chronic wounds, and other hard-to-heal conditions. By bridging the gap between preclinical research and clinical application, MediWound addresses critical unmet needs in the wound care sector. Its market position is bolstered by a robust pipeline of therapeutics designed to improve patient outcomes through advanced enzymatic debridement and tissue repair, positioning the firm as a key player in the intersection of biotechnology and emergency medical preparedness.
How much funding has MediWound raised?
MediWound has raised a total of $85.7M across 3 funding rounds:
Stock Offering
$70M
Unspecified
$9M
Other Financing Round
$6.7M
Stock Issuance/Offering (2014): $70M, investors not publicly disclosed
Unspecified (2022): $9M led by Biomedical Advanced Research and Development Authority (BARDA
Other Financing Round (2023): $6.7M supported by U.S. Department of Defense
Key Investors in MediWound
Biomedical Advanced Research and Development Authority (BARDA)
BARDA enhances the nation's public health security and emergency preparedness by facilitating communication on innovative medical countermeasures between federal agencies and public stakeholders.
U.S. Department of Defense
The U.S. Department of Defense is the federal department responsible for coordinating and supervising all agencies and functions of the government directly related to national security and the United States Armed Forces.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for MediWound?
With the recent influx of capital, MediWound is well-positioned to accelerate its strategic objectives, particularly in the expansion of its therapeutic portfolio and the strengthening of its manufacturing capabilities. The involvement of government-backed entities suggests a continued focus on national health security and the deployment of medical countermeasures for large-scale emergency scenarios. Moving forward, the company is expected to prioritize the regulatory advancement of its core assets, potentially seeking broader market penetration for its enzymatic solutions. Investors and stakeholders will likely monitor the firm's ability to translate this strategic financing into sustained commercial growth and long-term clinical efficacy in the global wound care market.
See full MediWound company page
